Latest Articles
Art show puts voice to women's unheard stories - Not Really Here Group
Art show puts voice to women's unheard stories Not Really Here Group
Published: June 24, 2026, 2:39 p.m.
Baylen Dupree tears up discussing possible infertility due to endometriosis: ‘Everything is unknown’ (exclusive) - MSN
Baylen Dupree tears up discussing possible infertility due to endometriosis: ‘Everything is unknown’ (exclusive) MSN
Published: June 24, 2026, 2:24 p.m.
Xella Health Launches to Uniquely Detect and Treat 130+ Often-Misdiagnosed Women's Health Conditions - insider.fitt.co
Xella Health Launches to Uniquely Detect and Treat 130+ Often-Misdiagnosed Women's Health Conditions insider.fitt.co
Published: June 24, 2026, 2:13 p.m.
Xella Health Launches to Uniquely Detect and Treat 130+ Often-Misdiagnosed Women's Health Conditions - Fitt Insider
Xella Health Launches to Uniquely Detect and Treat 130+ Often-Misdiagnosed Women's Health Conditions Fitt Insider
Published: June 24, 2026, 2:13 p.m.
EU committee warns of women’s health ‘blind spot’ - FemTech World
EU committee warns of women’s health ‘blind spot’ FemTech World
Published: June 24, 2026, 2:04 p.m.
Absci surges on Eli Lilly, private equity investments - MSN
Absci surges on Eli Lilly, private equity investments MSN
Published: June 24, 2026, 1:59 p.m.
Baylen Out Loud: Baylen Gets Emotional Amidst Baby Making Talks - Fears She Cannot Have Kids! - TV Season & Spoilers -
Baylen Out Loud: Baylen Gets Emotional Amidst Baby Making Talks - Fears She Cannot Have Kids! TV Season & Spoilers -
Published: June 24, 2026, 1:53 p.m.
Absci Raises $100 Million In Equity To Fund AI-Designed Hair Loss And Endometriosis Program - Benzinga
Absci Raises $100 Million In Equity To Fund AI-Designed Hair Loss And Endometriosis Program Benzinga
Published: June 24, 2026, 1:09 p.m.
WHO Guidelines: What You Must Know About the Endometriosis Crisis - streamlinefeed.co.ke
WHO Guidelines: What You Must Know About the Endometriosis Crisis streamlinefeed.co.ke
Published: June 24, 2026, 11:46 a.m.
Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR) - markets.businessinsider.com
Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR) markets.businessinsider.com
Published: June 24, 2026, 11:25 a.m.
Link copied to clipboard!